News

IIBm researchers discover a new way to grow cancer stem cells from pancreatic cancer

Dr. Bruno Sainz's research team ( www.sainzlab.com ), supported by the Spanish Association Against Cancer (AECC) and the Carmen Delgado/Miguel Pérez-Mateo Fellowship from AESPANC-ACANPAN, has published a new study in Nature Communications ( https://www.nature.com/articles/s41467-020-18954- z ) where they manage to cultivate, in a sustainable way, pancreatic cancer stem cells, the most aggressive cell type present within pancreatic cancer. The study, led by first author Dr. Sandra Valle, represents an important advance that should facilitate the identification of new targets and therapies against this tumor and these cells in particular. Cancer stem cells are one of the key cancer cell types that mediate tumor survival, as they are able to resist common chemotherapy and thus drive tumor relapse...

Cholesterolnitrones, a new family of antioxidant molecules for the treatment of hearing loss

The Neurobiology of Hearing group, led by Prof. Isabel Varela Nieto, will carry out trials in cellular and animal models throughout 2021 to evaluate the efficacy of cholesterolnithrones in the treatment of presbicusis and hearing loss associated to cisplatin ototoxicity. These small molecules are potent antioxidant agents which have shown a strong neuroprotective effect in in vitro studies, in neuronal primary cultures and in animal models of global and focal brain ischemia in rats and mice. The results of this works will be critical to confirm the potential of this molecule as a compound-lead for entry into the preclinical phase.   This project, in which the Medical Chemistry Laboratory of the Institute of General Organic Chemistry of the CSIC is also participating, led by Prof. José Luis Marco Contelles, has been selected by the Fundación General CSIC ...

A possible new therapy for pancreatic cancer

A study carried out with the participation of the team led by Dr. Bruno Sainz, Jr., a researcher at the "Alberto Sols" Biomedical Research Institute (IIBM-UAM) and supported by the Spanish Association Against Cancer (AECC), has identified a new Achilles' heel of pancreatic cancer stem cells: a part of the cell known as lysosomes, which represents a possible target for treating this type of cancer, one of the most aggressive of all malignancies.   Pancreatic cancer is a cancer that responds poorly to available treatments, due in part to the presence of cancer stem cells. This type of cell has the capacity to give rise to all of the other cancer cells present within the tumor and they are responsible for the origin of the tumor, its spread to other organs or metastasis, and relapse.    In order to find new...

The UAM, the IIBM (CSIC-UAM) and the FPCM receive the validation to carry out diagnostic PCR tests for Covid19

El Instituto de Investigaciones Biomédicas Alberto Sols (IIBM), centro mixto del Consejo Superior de Investigaciones Científicas (CSIC) y la Universidad Autónoma de Madrid (UAM), ha recibido la validación del Instituto de Salud Carlos III, dependiente del Ministerio de Ciencia e Innovación, para realizar las pruebas PCR de detección molecular del coronavirus SARS-CoV-2, causante de la pandemia de Covid-19. https://www.csic.es/es/actualidad-del-csic/la-uam-el-iibm-csic-uam-y-la-fpcm-reciben-la-validacion-para-realizar-pruebas

The IIBM receives a donation from ALANTRA for the diagnosis of COVID19

The company ALANTRA has made a donation of 305,000 euros to the Higher Council for Scientific Research (CSIC) for the acquisition of two robots and reagents for molecular diagnosis of COVID19 at the Alberto Sols Institute for Biomedical Research (IIBM). The IIBM, a joint center of the CSIC and the Autonomous University of Madrid, participates in an effort in collaboration with the Department of Public Health, Preventive Medicine and Microbiology of the UAM School of Medicine to launch a diagnostic platform for COVID19 by PCR. The start was initiated at the request of the Carlos Tercero Health Institute via UAM Vice-Rectorate for Research, which coordinates the operation. ALANTRA's donation represents a decisive boost to the effort being made to launch the diagnostic platform, since the two robots will allow the processing of a significant number of samples in a short...

Isabel Varela-Nieto highlights in El País journal the importance of noise as a cause of premature deafness

El País (Health section) published on September 8 an article about the consequences of excessive noise exposure, especially among young people. Professor Varela-Nieto, group leader of the U761 of CIBERER, pointed out that, according to World Health Organization, approximately 50% of young people between 12 and 35 are at risk of hearing loss due to their listening habits with headphones. Excessive noise damages the sensory cells of the ear, which lack regeneration capacity and therefore they are irreversibly lost. Dr. Luis Lassaletta, head of Otolaryngology Service at La Paz Hospital and an associated researcher in the U761 unit, confirmed the increase in the number of patients with hearing loss secondary to noise exposure, and urged young people to protect their ear and go to the specialist when first symptoms appear.   The full article can be consulted at:...

Isabel Varela-Nieto, awarded for her scientific career

Isabel Varela-Nieto, group leader of U761 CIBERER unit at Alberto Sols Biomedical Research Institute (CSIC-UAM), has been awarded with Morgagni medal for her professional career in the study of inner ear and hearing loss. Giovanni Battista Morgagni (1682 - 1771), doctor of Medicine and Philosophy, and professor at the University of Padua for more than 50 years, is considered the father of modern pathological anatomy.   Professor Varela-Nieto has been dedicated for last 30 years to the study of the molecular basis of auditory function and the pathophysiology of hearing loss, combining development studies in chicken embryos and in vivo assays with genetically modified mice. In recent years she has focused her research on rare hearing loss, both in animal models and in patients, in collaboration with clinicians at La Paz Hospital. She received the award from...

Pilar Santisteban appointed member of the Technical Scientific Committee of the State Research Agency

On April 30, Pilar Santisteban has been appointed member of the Technical Scientific Committee of the AEI. The proposal made by the Governing Committee of the Agency, is part of the consolidation phase of the Agency, where the scientific advice of the Committee will be essential.   The agency has a Director elected in Public Contest, and has established its new structure by developing autonomous administrative capacities. The director, with the advice of the Scientific and Technical Committee, is beginning to develop calls under the new organization. Participation in the Scientific Committee of our colleague is a pride for the institute and we take advantage of this platform to congratulate Pilar for her appointment.  

Engineered immune cells produce antibodies to fight HIV

Engineered immune cells produce antibodies to fight HIV   B cells that are removed from patients' bloodstreams and genetically altered may one day allow more effective vaccines for HIV, influenza and hepatitis   Alicia González Martín, principal investigator of the Institute for Biomedical Research Alberto Sols (IIBm-CSIC/UAM), has co-developed with James Voss, Raiees Andrabi and Dennis Burton from The Scripps Research Institute of California a new technique to engineer human primary B cells to produce antibodies that can neutralize, or disable, human immunodeficiency virus (HIV). This new technique could one day be used to generate new, broadly acting vaccines or therapies against not only HIV but other pathogens such as influenza and hepatitis. The study entitled: "Reprogramming the antigen specificity of B cells using...